Exelixis Inc (EXEL) Stock Price

EXELStock
$54.45+43.67%52W
Market Cap$13.49B
P/E15.99x
PEG Ratio2.56
Div yield
Beta0.47

EXEL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)8.69%
Price vs S&P 500 (4W)-2.65%
PEG Ratio2.56
VGM Score64.11
P/E Ratio (Annual)15.99x

EXEL Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026$0.86$0.91+5.20%(+$0.05)
Q1 2026$0.76$0.87+14.02%(+$0.11)
Q4 2025$0.81$0.94+16.17%(+$0.13)
Q3 2025$0.67$0.78+16.24%(+$0.11)
Q2 2025$0.65$0.75+16.24%(+$0.10)

EXEL Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.77
3.77
3.68
3.65

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
EXELExelixis Inc
CBB$54.45
AMGNAmgen IncCCB$432.42
GILDGilead Sciences IncCBB$145.68
ARGXargenx SE American Depositary SharesDAB$1023.21
MRNAModerna, Inc. Common StockDCA$137.99
RVMDRevolution Medicines, Inc. Common StockFA$207.88
BIIBBiogen Inc. Common StockCDB$218.50
BNTXBioNTech SE American Depositary ShareCCC$102.08
NBIXNeurocrine Biosciences IncCBC$154.06
HALOHalozyme Therapeutics, Inc.CBB$105.35
TECHBio-Techne Corp.DCB$72.35

About Exelixis Inc

Exelixis Inc is a biopharmaceutical company that discovers and commercializes oncology treatments. Its portfolio includes Cabometyx for renal cell and hepatocellular carcinoma, Cometriq for metastatic medullary thyroid cancer, and Cotellic (in partnership with Roche) for melanoma.